Skip to main content
Article thumbnail
Location of Repository

Efecto de la combinación rosiglitazona/metformin y de la monoterapia con metformin sobre los componentes del síndrome metabólico

By Antonio Pereira, Mariela Paoli, Valeri Lenin and Gabriela Arata-Bellabarba

Abstract

Objetivos: Comparar el efecto de la combinación rosiglitazona/metformin con el de metformin como monoterapia, sobre los componentes del síndrome metabólico (SM). Métodos: Se realizó un ensayo clínico, doble ciego, aleatorizado. Se incluyeron 25 pacientes de ambos sexos, entre 20 y 75 años que cumplían con los criterios diagnósticos de la ATP III para SM. Se les registró tensión arterial (TA), talla, peso y circunferencia abdominal (CA). Se calculó el índice de masa corporal (IMC). Se les determinó antes y a los 4 meses del tratamiento glicemia e insulinemia en ayunas y 2 horas post carga y perfil lipídico. Se calculó el índice HOMA. Los pacientes se distribuyeron aleatoriamente en dos grupos: Grupo A, 11 pacientes (10 mujeres y 1 hombre), edad promedio 43,45±14,98 quienes recibieron metformin (500 mg) combinado con rosiglitazona (2 mg) en una tableta dos veces al día; Grupo B, 14 pacientes (13 mujeres y 1 hombre), edad promedio 44,21±10,28 quienes recibieron metformin 850 mg en una tableta dos veces al día. Resultados: Las variables estudiadas no fueron diferentes entre ambos grupos, antes del tratamiento. Con ambos tratamientos, el IMC y la CA disminuyeron significativamente aunque el cambio porcentual fue mayor en el grupo A (IMC: 8,1% versus 3,4%; CA: 9,7% versus 4%; p<0,05). En el grupo A hubo disminución significativa del HOMA y la insulina en ayunas y postcarga. En el grupo B se observó disminución significativa de la TA y de los niveles de insulina en ayunas y postcarga y mejoría no significativa del HOMA. No se observaron cambios significativos en el perfil lipídico. Hubo una correlación positiva de la CA con el HOMA (r=0,618; p=0,0007). Conclusiones: Ambas terapias fueron beneficiosas en el tratamiento de los pacientes con SM, observándose, una mayor reducción de la CA y del HOMA en aquellos que recibieron la combinación rosiglitazona/metformin y una mayor reducción de las cifras tensionales en los que recibieron metformin como monoterapia.<br>Objective: To compare the effect of the combination rosiglitazone/metformin with the metformin as monotherapy, on the components of the metabolic syndrome (MS). Methods: A double blind, randomized, clinical study was carried out. Twenty five patients of both sexes, between 20 and 75 years of age, with the diagnosis of MS (ATP III criteria) were included. Blood pressure (BP), height, weight and abdominal circumference (AC) were registered. Fasting and 2 hours post load plasma glucose and insulin levels and fasting lipid profile were measured. The body mass index (BMI) and the HOMA index were calculated. The patients were distributed at random in two groups: Group A, 11 patients (10 women and 1 man), average age 43,45±14,98 who received metformin (500 mg) in combination with rosiglitazone (2 mg) in a tablet two times a day; Group B, 14 patients (13 women and 1 man), average age 44,21±10,28 who received metformin 850 mg in a tablet two times a day. Results: The studied variables were not different between both groups, before the treatment. With both treatments, the BMI and the AC diminished significantly though the percentage of change was bigger in the group A (BMI: 8,1 % versus 3,4 %; AC: 9,7 % versus 4 %; p <0,05). There was a significant decrease of the HOMA index and the fasting and post load insulin levels in the group A. In the group B was observed significant decrease of the values of BP and of the fasting and postload insulin levels and a not significant improvement of the HOMA index. Significant changes were not observed in the lipid profile. There was a positive correlation of the AC with the HOMA index (r=0,618; p=0,0007). Conclusions: Both therapies were beneficial in the treatment of the patients with MS. A major reduction of the AC and of the HOMA index in those who received the combination rosiglitazone/metformin and a major reduction of the values of blood pressure in those who received metformin as monotherapy were observed

Topics: Síndrome Metabólico, metformin, rosiglitazona, Metabolic Syndrome, metformin, rosiglitazone, LCC:Diseases of the endocrine glands. Clinical endocrinology, LCC:RC648-665, LCC:Specialties of internal medicine, LCC:RC581-951, LCC:Internal medicine, LCC:RC31-1245, LCC:Medicine, LCC:R, DOAJ:Internal medicine, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: Sociedad Venezolana de Endocrinología y Metabolismo
Year: 2008
OAI identifier: oai:doaj.org/article:6ceae1993be446c4bbed2aa51020330d
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://doaj.org/search?source=... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.